IS5865A - Lyfjasamsetningar með stýrða losun sem innihalda CGMP PDE-5 lata - Google Patents

Lyfjasamsetningar með stýrða losun sem innihalda CGMP PDE-5 lata

Info

Publication number: IS5865A
Authority: IS; Iceland
Prior art keywords: inhibitors; controlled; pharmaceutical compositions; compositions containing; release pharmaceutical
Prior art date: 1998-10-23

Application number

IS5865A

Other languages

English (en)

Inventor

King Elizabeth

James Macrae Ross

Original Assignee

Pfizer Research And Development Company, N.V./S.A.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-10-23

Filing date

2001-02-27

Publication date

2001-02-27

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27269526&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS5865(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1998-10-23 Priority claimed from GBGB9823192.1A external-priority patent/GB9823192D0/en

1998-11-16 Priority claimed from GBGB9825117.6A external-priority patent/GB9825117D0/en

1998-11-27 Priority claimed from GBGB9826392.4A external-priority patent/GB9826392D0/en

2001-02-27 Application filed by Pfizer Research And Development Company, N.V./S.A. filed Critical Pfizer Research And Development Company, N.V./S.A.

2001-02-27 Publication of IS5865A publication Critical patent/IS5865A/is

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Reproductive Health (AREA)
Endocrinology (AREA)
Neurosurgery (AREA)
Gynecology & Obstetrics (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

IS5865A 1998-10-23 2001-02-27 Lyfjasamsetningar með stýrða losun sem innihalda CGMP PDE-5 lata IS5865A (is)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
GBGB9823192.1A GB9823192D0 (en)	1998-10-23	1998-10-23	Pharmaceutical formulations
GBGB9825117.6A GB9825117D0 (en)	1998-11-16	1998-11-16	Pharmaceutical formulations
GBGB9826392.4A GB9826392D0 (en)	1998-11-27	1998-11-27	Pharmaceutical formulations
PCT/IB1999/001619 WO2000024383A1 (en)	1998-10-23	1999-10-04	Controlled-release pharmaceutical formulations containing a cgmp pde-5 inhibitor

Publications (1)

Publication Number	Publication Date
IS5865A true IS5865A (is)	2001-02-27

Family

ID=27269526

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IS5865A IS5865A (is)	1998-10-23	2001-02-27	Lyfjasamsetningar með stýrða losun sem innihalda CGMP PDE-5 lata

Country Status (44)

Country	Link
US (1)	US6964780B1 (is)
EP (1)	EP1123088B1 (is)
JP (1)	JP2002528408A (is)
KR (1)	KR20010075659A (is)
CN (1)	CN1324233A (is)
AP (1)	AP2001002125A0 (is)
AT (1)	ATE340562T1 (is)
AU (1)	AU756509B2 (is)
BG (1)	BG65323B1 (is)
BR (1)	BR9914718A (is)
CA (1)	CA2348086C (is)
CO (1)	CO5160262A1 (is)
CR (1)	CR6326A (is)
CY (1)	CY1106239T1 (is)
CZ (1)	CZ20011427A3 (is)
DE (1)	DE69933383T2 (is)
DK (1)	DK1123088T3 (is)
DZ (1)	DZ2923A1 (is)
EA (1)	EA004068B1 (is)
EE (1)	EE200100235A (is)
ES (1)	ES2272082T3 (is)
GT (1)	GT199900184A (is)
HK (1)	HK1041818A1 (is)
HR (1)	HRP20010285A2 (is)
HU (1)	HUP0104318A3 (is)
ID (1)	ID28232A (is)
IL (1)	IL141764A (is)
IS (1)	IS5865A (is)
MA (1)	MA26700A1 (is)
MX (1)	MXPA01004011A (is)
MY (1)	MY130727A (is)
NO (1)	NO20011933L (is)
NZ (1)	NZ510275A (is)
OA (1)	OA11664A (is)
PA (1)	PA8484301A1 (is)
PE (1)	PE20001286A1 (is)
PL (1)	PL195789B1 (is)
PT (1)	PT1123088E (is)
SK (1)	SK286473B6 (is)
TR (1)	TR200101103T2 (is)
TW (1)	TW577756B (is)
UA (1)	UA67802C2 (is)
UY (1)	UY25765A1 (is)
WO (1)	WO2000024383A1 (is)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2309332C (en) *	1997-11-12	2002-12-03	Bayer Aktiengesellschaft	2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
WO2000025752A1 (en)	1998-11-02	2000-05-11	Church, Marla, J.	Multiparticulate modified release composition
KR101197919B1 (ko)	1999-10-29	2012-11-29	유로-셀티크 소시에떼 아노뉨	서방성 하이드로코돈 제형
US10179130B2 (en)	1999-10-29	2019-01-15	Purdue Pharma L.P.	Controlled release hydrocodone formulations
US7501409B2 (en)	2000-09-06	2009-03-10	Mitsubishi Tanabe Pharma Corporation	Preparations for oral administration
US6733783B2 (en)	2000-10-30	2004-05-11	Euro-Celtique S.A.	Controlled release hydrocodone formulations
AU2002230217B2 (en) *	2001-02-15	2005-02-17	Tanabe Seiyaku Co., Ltd.	Tablets quickly disintegrated in oral cavity
US10675280B2 (en)	2001-10-20	2020-06-09	Sprout Pharmaceuticals, Inc.	Treating sexual desire disorders with flibanserin
UA78974C2 (en)	2001-10-20	2007-05-10	Boehringer Ingelheim Pharma	Use of flibanserin for treating disorders of sexual desire
ITMI20020515A1 (it) *	2002-03-12	2003-09-12	Jagotec Ag	Sistema per il rilasco controllato di uno o piu' principi attivi
GB0318824D0 (en) *	2003-08-11	2003-09-10	Glaxo Group Ltd	Novel composition
DE102004023069A1 (de)	2004-05-11	2005-12-08	Bayer Healthcare Ag	Neue Darreichungsformen des PDE 5-Inhibitors Vardenafil
RU2436579C2 (ru)	2004-05-11	2011-12-20	Эмоушнл Брэйн Б.В.	Фармацевтические композиции и их применение в лечении женской сексуальной дисфункции
GB0421121D0 (en) *	2004-09-22	2004-10-27	Natrocell Technologies Ltd	Composite rodenticide
DE102005001989A1 (de) *	2005-01-15	2006-07-20	Bayer Healthcare Ag	Intravenöse Formulierungen von PDE-Inhibitoren
DE102005009240A1 (de)	2005-03-01	2006-09-07	Bayer Healthcare Ag	Arzneiformen mit verbesserten pharmakokinetischen Eigenschaften
DE102005009241A1 (de) *	2005-03-01	2006-09-07	Bayer Healthcare Ag	Arzneiformen mit kontrollierter Bioverfügbarkeit
EP1896076A2 (en) *	2005-06-27	2008-03-12	Daniel Drai	Compositions and methods for enhancement of sexual function
WO2007014929A1 (en)	2005-08-03	2007-02-08	Boehringer Ingelheim International Gmbh	Use of flibanserin in the treatment of obesity
SG166106A1 (en) *	2005-09-29	2010-11-29	Bayer Schering Pharma Ag	Pde inhibitors and combinations thereof for the treatment of urological disorders
JP2009513604A (ja)	2005-10-29	2009-04-02	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	月経前障害及び他の女性の性的障害治療用のベンゾイミダゾロン誘導体
EP1790343A1 (en)	2005-11-11	2007-05-30	Emotional Brain B.V.	Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction
WO2008000760A1 (en)	2006-06-30	2008-01-03	Boehringer Ingelheim International Gmbh	Flibanserin for the treatment of urinary incontinence and related diseases
BRPI0716439B8 (pt)	2006-08-14	2021-05-25	Boehringer Ingelheim Int	sistemas de liberação farmacêutico compreendendo flibanserina, processo para preparação e uso dos mesmos
BRPI0716436B8 (pt)	2006-08-25	2021-05-25	Boehringer Ingelheim Int	sistema de liberação controlada e método para fabricação do mesmo
EP1925307A1 (en)	2006-11-03	2008-05-28	Emotional Brain B.V.	Use of 3-alpha-androstanediol in the treatment of sexual dysfunction
US20080226715A1 (en) *	2007-03-16	2008-09-18	Albert Cha	Therapeutic compositions and methods
KR20100029762A (ko) *	2007-06-13	2010-03-17	바이엘 쉐링 파마 악티엔게젤샤프트	청력 장애 치료용 ｐｄｅ 억제제
PE20091188A1 (es)	2007-09-12	2009-08-31	Boehringer Ingelheim Int	Compuesto 1-[2-(4-(3-trifluorometil-fenil)piperazin-1-il)etil]-2,3-dihidro-1h-benzimidazol-2-ona (flibanserina), sus sales de adicion y composiciones farmaceuticas que los contienen
US20110033506A1 (en) *	2008-02-08	2011-02-10	Adel Penhasi	Combination dosage form of low-dose modafinil and low-dose sildenafil
BRPI0823356A2 (pt) *	2008-12-12	2015-06-16	Rhein Siegfried Sa De Cv	Composição de liberação pulsátil de sildenafil e processo para prepará-la
KR101004205B1 (ko) *	2008-12-17	2010-12-24	동아제약주식회사	유데나필 함유 서방성 제제를 제조하기 위한 제어방출 조성물
EA015250B9 (ru) *	2010-11-19	2013-10-30	Тева Фармасьютикал Индастриз, Лтд.	Таблетка силденафила, обеспечивающая модифицированную фармакокинетику, и способ ее изготовления
WO2012158030A2 (en)	2011-05-13	2012-11-22	Emotional Brain B.V.	Drug delivery system
US20140328911A1 (en) *	2011-07-22	2014-11-06	Pom Wonderful. Llc	Compositions comprising pomegranate polyphenols in combination with erectile dysfunction-treating compounds, and methods of treating erectile dysfunction therewith
WO2017168174A1 (en) *	2016-04-02	2017-10-05	N4 Pharma Uk Limited	New pharmaceutical forms of sildenafil
CN113995727B (zh) *	2021-11-08	2023-04-07	山东鲁抗医药股份有限公司	一种5型磷酸二酯酶抑制剂片剂及其制备方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3952741A (en)	1975-01-09	1976-04-27	Bend Research Inc.	Controlled release delivery system by an osmotic bursting mechanism
JPS54119021A (en) *	1978-03-06	1979-09-14	Nippon Kayaku Co Ltd	Carcinostatic agent
CH648754A5 (en) *	1979-08-16	1985-04-15	Ciba Geigy Ag	Pharmaceutical slow release tablet
JPS5748908A (en) *	1980-09-08	1982-03-20	Kyorin Pharmaceut Co Ltd	Prolonged release type nicomol pharmaceutical
FR2624732B1 (fr)	1987-12-21	1991-02-15	Synthelabo	Formulation pharmaceutique a liberation prolongee
MC2025A1 (fr) *	1988-04-20	1990-04-25	Asta Pharma Ag	Medicament contenant de l'azelastine et capable de liberer celle-ci de facon controlee
IT1229856B (it) *	1989-04-20	1991-09-13	Recordati Chem Pharm	Compresse a rilascio controllato contenenti flavossato.
US5474784A (en)	1990-03-02	1995-12-12	British Technology Group Limited	Dispensing device
GB9013750D0 (en)	1990-06-20	1990-08-08	Pfizer Ltd	Therapeutic agents
GB9114760D0 (en)	1991-07-09	1991-08-28	Pfizer Ltd	Therapeutic agents
ES2149250T3 (es) *	1993-04-23	2000-11-01	Novartis Ag	Dispositivo para la administracion de medicamentos con liberacion controlada.
GB9311920D0 (en) *	1993-06-09	1993-07-28	Pfizer Ltd	Therapeutic agents
US5464633A (en)	1994-05-24	1995-11-07	Jagotec Ag	Pharmaceutical tablets releasing the active substance after a definite period of time
US5656629A (en) *	1995-03-10	1997-08-12	Sanofi Winthrop, Inc.	6-substituted pyrazolo (3,4-d)pyrimidin-4-ones and compositions and methods of use thereof
US5888534A (en)	1995-06-13	1999-03-30	Pentech Pharmaceuticals, Inc.	Controlled release of drugs delivered by sublingual or buccal administration
GB9514464D0 (en) *	1995-07-14	1995-09-13	Glaxo Lab Sa	Medicaments
GB9523752D0 (en) *	1995-11-21	1996-01-24	Pfizer Ltd	Pharmaceutical formulations
JPH1067657A (ja) *	1996-06-18	1998-03-10	Otsuka Pharmaceut Co Ltd	マルチプルユニット型持続性製剤
AU2976897A (en) *	1996-06-18	1998-01-07	Otsuka Pharmaceutical Co., Ltd.	Multiple-unit type prolonged action drug preparation
HUP0002744A3 (en) *	1997-01-06	2001-01-29	Pfizer	Rapidly releasing and taste-masking pharmaceutical dosage form
US6046177A (en) *	1997-05-05	2000-04-04	Cydex, Inc.	Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
US5874418A (en) *	1997-05-05	1999-02-23	Cydex, Inc.	Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
US6403597B1 (en) *	1997-10-28	2002-06-11	Vivus, Inc.	Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
US6277884B1 (en) *	1998-06-01	2001-08-21	Nitromed, Inc.	Treatment of sexual dysfunction with N-hydroxyguanidine compounds
ES2220109T3 (es) *	1998-09-04	2004-12-01	Ortho-Mcneil Pharmaceutical, Inc.	5-heterociclilpirazolo (4,3-d) pirimidin-7-onas para el tratamiento de la disfuncion erectil masculina.

1999
- 1999-04-10 UA UA2001042718A patent/UA67802C2/uk unknown
- 1999-10-01 TW TW088116973A patent/TW577756B/zh not_active IP Right Cessation
- 1999-10-04 EP EP99946377A patent/EP1123088B1/en not_active Expired - Lifetime
- 1999-10-04 HR HR20010285A patent/HRP20010285A2/xx not_active Application Discontinuation
- 1999-10-04 BR BR9914718-1A patent/BR9914718A/pt not_active Application Discontinuation
- 1999-10-04 TR TR2001/01103T patent/TR200101103T2/xx unknown
- 1999-10-04 CA CA002348086A patent/CA2348086C/en not_active Expired - Fee Related
- 1999-10-04 CZ CZ20011427A patent/CZ20011427A3/cs unknown
- 1999-10-04 DE DE69933383T patent/DE69933383T2/de not_active Expired - Fee Related
- 1999-10-04 AP APAP/P/2001/002125A patent/AP2001002125A0/en unknown
- 1999-10-04 EE EEP200100235A patent/EE200100235A/xx unknown
- 1999-10-04 DK DK99946377T patent/DK1123088T3/da active
- 1999-10-04 ES ES99946377T patent/ES2272082T3/es not_active Expired - Lifetime
- 1999-10-04 WO PCT/IB1999/001619 patent/WO2000024383A1/en not_active Ceased
- 1999-10-04 PT PT99946377T patent/PT1123088E/pt unknown
- 1999-10-04 IL IL141764A patent/IL141764A/en unknown
- 1999-10-04 CN CN99812510A patent/CN1324233A/zh active Pending
- 1999-10-04 AT AT99946377T patent/ATE340562T1/de not_active IP Right Cessation
- 1999-10-04 ID IDW20010891A patent/ID28232A/id unknown
- 1999-10-04 MX MXPA01004011A patent/MXPA01004011A/es active IP Right Grant
- 1999-10-04 EA EA200100298A patent/EA004068B1/ru not_active IP Right Cessation
- 1999-10-04 SK SK519-2001A patent/SK286473B6/sk unknown
- 1999-10-04 KR KR1020017005042A patent/KR20010075659A/ko not_active Ceased
- 1999-10-04 JP JP2000577993A patent/JP2002528408A/ja active Pending
- 1999-10-04 OA OA1200100093A patent/OA11664A/en unknown
- 1999-10-04 NZ NZ510275A patent/NZ510275A/en unknown
- 1999-10-04 AU AU58787/99A patent/AU756509B2/en not_active Ceased
- 1999-10-04 HK HK02103588.0A patent/HK1041818A1/zh unknown
- 1999-10-04 HU HU0104318A patent/HUP0104318A3/hu unknown
- 1999-10-04 PL PL99347476A patent/PL195789B1/pl not_active IP Right Cessation
- 1999-10-18 PA PA19998484301A patent/PA8484301A1/es unknown
- 1999-10-20 DZ DZ990223A patent/DZ2923A1/xx active
- 1999-10-20 MY MYPI99004535A patent/MY130727A/en unknown
- 1999-10-20 MA MA25820A patent/MA26700A1/fr unknown
- 1999-10-21 PE PE1999001062A patent/PE20001286A1/es not_active Application Discontinuation
- 1999-10-22 GT GT199900184A patent/GT199900184A/es unknown
- 1999-10-22 UY UY25765A patent/UY25765A1/es not_active Application Discontinuation
- 1999-10-22 CO CO99066970A patent/CO5160262A1/es unknown
- 1999-10-22 US US09/425,622 patent/US6964780B1/en not_active Expired - Fee Related
2001
- 2001-02-27 IS IS5865A patent/IS5865A/is unknown
- 2001-03-14 CR CR6326A patent/CR6326A/es not_active Application Discontinuation
- 2001-04-19 NO NO20011933A patent/NO20011933L/no not_active Application Discontinuation
- 2001-04-24 BG BG105465A patent/BG65323B1/bg unknown
2006
- 2006-11-13 CY CY20061101644T patent/CY1106239T1/el unknown

Also Published As

Publication number	Publication date
SK5192001A3 (en)	2002-09-10
EA200100298A1 (ru)	2001-08-27
SK286473B6 (sk)	2008-11-06
IL141764A0 (en)	2002-03-10
DE69933383D1 (de)	2006-11-09
NO20011933L (no)	2001-06-25
CY1106239T1 (el)	2011-06-08
AU5878799A (en)	2000-05-15
AU756509B2 (en)	2003-01-16
PL195789B1 (pl)	2007-10-31
ES2272082T3 (es)	2007-04-16
IL141764A (en)	2008-06-05
CA2348086C (en)	2007-01-23
US6964780B1 (en)	2005-11-15
EP1123088B1 (en)	2006-09-27
NO20011933D0 (no)	2001-04-19
OA11664A (en)	2005-01-07
TR200101103T2 (tr)	2001-09-21
BR9914718A (pt)	2001-07-10
BG65323B1 (bg)	2008-02-29
BG105465A (bg)	2001-12-29
CR6326A (es)	2004-02-23
JP2002528408A (ja)	2002-09-03
CN1324233A (zh)	2001-11-28
WO2000024383A1 (en)	2000-05-04
CO5160262A1 (es)	2002-05-30
EE200100235A (et)	2002-08-15
CZ20011427A3 (cs)	2001-10-17
TW577756B (en)	2004-03-01
MA26700A1 (fr)	2004-12-20
HRP20010285A2 (en)	2002-06-30
ATE340562T1 (de)	2006-10-15
DE69933383T2 (de)	2007-02-01
CA2348086A1 (en)	2000-05-04
MXPA01004011A (es)	2003-03-10
GT199900184A (es)	2001-04-14
DK1123088T3 (da)	2007-01-02
PE20001286A1 (es)	2000-11-22
HUP0104318A2 (hu)	2002-03-28
ID28232A (id)	2001-05-10
KR20010075659A (ko)	2001-08-09
EP1123088A1 (en)	2001-08-16
HUP0104318A3 (en)	2003-12-29
PL347476A1 (en)	2002-04-08
HK1041818A1 (zh)	2002-07-26
UA67802C2 (uk)	2004-07-15
PT1123088E (pt)	2007-01-31
UY25765A1 (es)	2001-08-27
NZ510275A (en)	2003-07-25
AP2001002125A0 (en)	2001-04-04
EA004068B1 (ru)	2003-12-25
MY130727A (en)	2007-07-31
PA8484301A1 (es)	2000-09-29
DZ2923A1 (fr)	2004-03-01

Publication	Publication Date	Title
IS5865A (is)	2001-02-27	Lyfjasamsetningar með stýrða losun sem innihalda CGMP PDE-5 lata
HUP0301114A3 (en)	2004-11-29	Pyrrolo[2,3-d]pyrimidine compounds as immunosuppressive agents and pharmaceutical compositions containing them
IS6304A (is)	2002-03-18	Kínasólínefnasambönd og lyfjafræðilegar efnasamsetningar sem innihalda þau
HUP0200355A3 (en)	2004-07-28	4-aminopyrrolopyrimidines as kinase inhibitors, pharmaceutical compositions containing them and their use
IL158079A0 (en)	2004-03-28	Pharmaceutical compositions containing an interleukin-6 antagonist
MA24878A1 (fr)	1999-12-31	Compositions de parfum
HUP0401819A3 (en)	2009-06-29	Pyrazole compounds useful as protein kinase inhibitors and pharmaceutical compositions containing them
HUP0400641A3 (en)	2010-03-29	Pyrazole compounds useful as protein kinase inhibitors and pharmaceutical compositions containing them
IL151530A0 (en)	2003-04-10	Compositions containing alpha-2-adrenergic agonist components
IL150447A0 (en)	2002-12-01	Pharmaceutical compositions containing entecavir
PL369404A1 (en)	2005-04-18	Impact-resistant polyolefin compositions
GB0001621D0 (en)	2000-03-15	Pharmaceutical compositions
DE69942465D1 (de)	2010-07-15	Antiparasitäre Zusammensetzungen
PL373301A1 (en)	2005-08-22	Phosphodiesterase 4 inhibitors
EG24194A (en)	2008-10-14	5ht-a-partial agonist pharmaceutical compositions
HUP0400644A3 (en)	2009-06-29	Pharmaceutical compositions containing aspirin
IL161430A0 (en)	2004-09-27	Pharmaceutical compositions containing ecteinascidin 743
GB2370841B (en)	2003-02-26	High solid paint compositions
HUP0103382A2 (en)	2002-06-29	Naaladase inhibitors useful as pharmaceutical compounds and compositions
GB0129489D0 (en)	2002-01-30	Sustained-release compositions
HUP0400654A3 (en)	2011-07-28	Substituted 8-arylquinoline phosphodiesterase 4 inhibitors and pharmaceutical compositions containing them
GB0023449D0 (en)	2000-11-08	Coating compositions
IS5958A (is)	2001-05-31	3, 4, 5-þrístaðgengin arýlnítronefnasambönd og lyfjablöndur sem slík efnasambönd eru í
GB0008485D0 (en)	2000-05-24	Pharmaceutical compositions
DE69918180D1 (de)	2004-07-22	Kathodische elektrotauchlackzusammensetzung